Summit Therapeutics EBITDA 2015-2025 | SMMT

Summit Therapeutics EBITDA for the quarter ending March 31, 2025 was $-0.067B, a 57.75% increase year-over-year.

  • Summit Therapeutics 2024 EBITDA was -0.226B, a 62.93% decline from 2023.
  • Summit Therapeutics 2023 EBITDA was -0.609B, a 775.96% increase from 2022.
  • Summit Therapeutics 2022 EBITDA was -0.07B, a 16.91% decline from 2021.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.

Summit Therapeutics EBITDA 2015-2025 | SMMT

  • Summit Therapeutics 2024 EBITDA was -0.226B, a 62.93% decline from 2023.
  • Summit Therapeutics 2023 EBITDA was -0.609B, a 775.96% increase from 2022.
  • Summit Therapeutics 2022 EBITDA was -0.07B, a 16.91% decline from 2021.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.